DLBCL - Diffuse Large B Cell Lymphoma Clinical Trials

47 clinical trials for DLBCL - Diffuse Large B Cell Lymphoma across international registries, including 28 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — RECRUITING · PHASE3
• Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma. — RECRUITING · PHASE3
• Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL — RECRUITING · PHASE2
• This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) — RECRUITING · PHASE2
• Long-term Study to Evaluate Safety and Persistence of GF-CART01 — RECRUITING
• CAR-T Followed by Bispecific Antibodies — RECRUITING · PHASE2
• Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma — RECRUITING · PHASE1
• A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma — RECRUITING · PHASE1
• SynKIR-310 for Relapsed/Refractory B-NHL — RECRUITING · PHASE1
• Glofitamab in Chinese Patients With R/R DLBCL — RECRUITING
• Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ — RECRUITING · PHASE2
• DALY II Japan/MB-CART2019.1 for DLBCL — RECRUITING · PHASE2
• Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma — RECRUITING · PHASE3
• A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma — RECRUITING · PHASE2
• Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta — RECRUITING · PHASE1
• Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL — RECRUITING · PHASE2
• Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers — RECRUITING · NA
• Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL — RECRUITING
• Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes — RECRUITING · PHASE2
• Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL — RECRUITING · PHASE2
• AZA Combined With RCHOP in P53-mutated DLBCL. — RECRUITING · PHASE2
• Real-World Study of DLBCL With Different Genetic Subtypes — RECRUITING
• Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL — RECRUITING · PHASE2
• Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study — RECRUITING · PHASE2
• Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict) — RECRUITING
• Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL — RECRUITING · PHASE2
• Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) — RECRUITING
• Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL — NOT_YET_RECRUITING · PHASE2
• Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL — NOT_YET_RECRUITING · PHASE2
• Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma — NOT_YET_RECRUITING · PHASE2
• Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma — NOT_YET_RECRUITING · PHASE2
• Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life — COMPLETED
• P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP — NOT_YET_RECRUITING · PHASE2
• A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping — NOT_YET_RECRUITING · PHASE3
• Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma — NOT_YET_RECRUITING
• Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL — NOT_YET_RECRUITING · NA
• Glofitamab Combined With CAR-T Therapy in R/R DLBCL — NOT_YET_RECRUITING · PHASE2
• Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma — NOT_YET_RECRUITING · PHASE2
• Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up — COMPLETED
• ImmunoMRI for Assessment of Tumor-associated Macrophages — NOT_YET_RECRUITING · PHASE1
• A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 — NOT_YET_RECRUITING · PHASE2
• An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme — ACTIVE_NOT_RECRUITING
• AZA Combined with R-GemOx for Elderly DLBCL Patients — NOT_YET_RECRUITING · PHASE2
• Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies — OTHER · PHASE1

Refine this search